BioSpace News Archive

Akero Therapeutics, Inc. has received a Breakthrough Therapy Designation from the US Food and Drug Administration (FDA) for the treatment of nonalcoholic steatohepatitis (NASH).

Instil Bio, Inc. today announced a reprioritization of its clinical programs to focus on development of its CoStAR-TIL product candidates.

Cabaletta Bio, Inc. today announced that it has agreed to sell, by way of an underwritten public offering, pre-funded warrants, in lieu of common stock.

Numinus Wellness Inc. today announced that its research division has submitted a clinical trial application to Health Canada to begin a new experiential training study that will enable practitioners training to provide Psilocybin-Assisted Therapy (PAT) the ability to experience and observe psilocybin sessions to further their understanding and PAT education.

Baudax Bio, Inc. today announced the initiation of a clinical study evaluating the safety, tolerability profile, and intubation conditions of BX1000 for neuromuscular blockade (NMB) in patients undergoing elective surgery.

iCAD, Inc. will be featured in the next “ProFound Insights, ProFound Impact” webinar, on Dec. 14 at 3 pm EST / 12 pm PST.

PathomIQ Inc., today announced the application of an AI-powered tool to predict response to Neoadjuvant Chemotherapy (NAC) in patients with Triple Negative Breast Cancer (TNBC) presented at the San Antonio Breast Cancer Symposium (SABCS), held from December 6-10, 2022.

RELIEF THERAPEUTICS Holding SA (SIX: RLF, OTCQB: RLFTF, RLFTY) (“Relief”), a Swiss, commercial-stage biopharmaceutical company identifying, developing and commercializing novel, patent-protected products in select specialty, rare and ultra-rare disease areas on a global basis, today announced the appointments of Jack Weinstein, MBA, to chief executive officer, and Jeremy Meinen, CPA, to chief financial officer, effective immediately.

Hansa Biopharma announces that the Italian Medicine Agency has granted full access and reimbursement for the use of Idefirix®, the company’s first-in-class treatment, for the desensitization of highly sensitized adult patients prior to kidney transplant from a deceased donor.

Molecular Targeting Technologies, Inc. (MTTI), a clinical stage radiopharmaceutical therapy company focused on therapies for rare diseases, announced today the allowance of an Investigational New Drug (IND) application by the U.S. Food and Drug Administration (FDA).